Oncology
Clinical Study
High Frequency of Metastatic Leydig Cell Testicular TumoursFarkas L.M.a · Székely J.G.a · Pusztai C.a · Baki M.baDepartment of Urology, Medical School of Pécs University, Pécs, and bNational Institute of Oncology, Budapest, Hungary
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: August 25, 2000
Issue release date: August 2000
Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 2
ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)
For additional information: https://www.karger.com/OCL
Abstract
690 patients were treated for testicular tumour in the course of 18 years. The histology of 7 cases showed Leydig cell tumour. In 4 of the 7 cases, a metastatic process leading to death was observed. At the time of diagnosis, 5 patients were found to have low stage, whereas 2 of the patients had advanced lymphatic involvement. The hematogenous and lymphatic metastases proved to be resistant to chemotherapy. Contrary to the major part of the literature, retroperitoneal lymphadenectomy should be performed with this histological type for the exact pathological staging immediately following orchiectomy.
© 2000 S. Karger AG, Basel
Related Articles:
References
- Belville WD, Insalaco SJ, Dresner ML, Buck AS: Benign testis tumors. J Urol 1982;128:1198–1200.
- Dilworth JP, Farrow GM, Oesterling JE: Non-germ cell tumours of the testis. Urology 1991;37:399–417.
- Bertram KA, Bratloff B, Hodges GF, Davidson M: Treatment of malignant Leydig cell tumor. Cancer 1991;68:2324–2329.
-
Bokemeyer C, Harstrick A, Gonnermann O, Schöber C, Kuczyk M, Poliwoda H, Schmoll H: Metastatic Leydig cell tumors of the testis: Report of four cases and review of the literature. Int J Oncol 1993;2:241–244.
- Grem JL, Robins HI, Willson KS, Gilchrist K, Trump DL: Metastatic Leydig cell tumor of the testis. Cancer 1986;58:2116–2119.
- Schwarzman MI, Russo P, Bosl GJ, Whitmore WF: Hormone-secreting metastatic interstitial cell tumour of the testis. J Urol 1989;141:620–622.
- Ünlüer E, Özcan D, Altin S: Malignant Leydig cell tumour of the testis: A case report and review of the literature. Int Urol Nephrol 1990;22:455–460.
- Coakley FV, Hricak H, Presti JC: Imaging and management of atypical testicular masses. Urol Clin North Am 1998;25:375–382.
- Cheville JC: Classification and pathology of testicular germ cell and sex cord-stromal tumors. Urol Clin North Am 1999;26:595–609.
- Fossa SD: Rare and unusual tumours of the genitourinary tract. Curr Opin Oncol 1992;4:463–468.
- Middendorff R, Davidoff MS, Mayer B, Holstein AF: Neuroendocrine characteristics of human Leydig cell tumours. Andrologia 1995;27:351–355.
-
Kim I, Young RH, Scully RE: Leydig cell tumors of the testis Am J Surg Pathol 1985;9:177–192.
- Iczkowski KA, Bostwick DG, Roche PC, Cheville JC: Inhibin A is a sensitive and specific marker for testicular sex cord-stromal tumors. Mod Pathol 1998;11:774–779.
- Cheville JC, Sebo TJ, Lager DJ, Bostwick DG, Farrow GM: Leydig cell tumor of the testis: A clinicopathologic, DNA content, and MIB-1 comparison of nonmetastasizing and metastasizing tumors. Am J Surg Pathol 1998;22:1361–1367.
Article / Publication Details
Published online: August 25, 2000
Issue release date: August 2000
Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 2
ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)
For additional information: https://www.karger.com/OCL
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
